Cardlytics Inc (NASDAQ:CDLX) CEO Scott D. Grimes Sells 6,000 Shares

Cardlytics Inc (NASDAQ:CDLX) CEO Scott D. Grimes sold 6,000 shares of the firm’s stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $30.99, for a total value of $185,940.00. The sale was disclosed in a filing with the SEC, which is accessible through this link.

NASDAQ:CDLX opened at $32.90 on Friday. Cardlytics Inc has a fifty-two week low of $9.80 and a fifty-two week high of $34.30. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.37 and a quick ratio of 2.37. The company has a market cap of $618.63 million, a PE ratio of -15.37 and a beta of 1.76. The company’s 50-day simple moving average is $27.77.

Cardlytics (NASDAQ:CDLX) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.12) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.35) by $0.23. Cardlytics had a negative return on equity of 84.02% and a negative net margin of 25.53%. The business had revenue of $48.73 million for the quarter, compared to analysts’ expectations of $43.77 million. During the same quarter in the previous year, the business posted ($0.21) EPS. Cardlytics’s revenue for the quarter was up 37.0% on a year-over-year basis. Equities analysts anticipate that Cardlytics Inc will post -1.12 earnings per share for the current year.

A number of equities analysts have issued reports on CDLX shares. Raymond James raised their target price on Cardlytics from $24.00 to $40.00 and gave the stock an “outperform” rating in a report on Friday. SunTrust Banks raised their target price on Cardlytics from $25.00 to $35.00 and gave the stock a “buy” rating in a report on Friday. Zacks Investment Research cut Cardlytics from a “buy” rating to a “hold” rating in a report on Tuesday, July 23rd. ValuEngine cut Cardlytics from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 23rd. Finally, Bank of America reiterated a “buy” rating and set a $32.00 price objective (up previously from $22.00) on shares of Cardlytics in a report on Wednesday, July 24th. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. Cardlytics has a consensus rating of “Buy” and a consensus target price of $30.71.

Large investors have recently added to or reduced their stakes in the company. Bank of Montreal Can lifted its holdings in shares of Cardlytics by 16,371.4% during the 2nd quarter. Bank of Montreal Can now owns 1,153 shares of the company’s stock valued at $30,000 after purchasing an additional 1,146 shares in the last quarter. Oppenheimer Asset Management Inc. acquired a new stake in Cardlytics in the 2nd quarter valued at approximately $60,000. Rockefeller Capital Management L.P. acquired a new stake in Cardlytics in the 2nd quarter valued at approximately $85,000. Acadian Asset Management LLC acquired a new stake in Cardlytics in the 2nd quarter valued at approximately $161,000. Finally, Gamco Investors INC. ET AL acquired a new position in shares of Cardlytics during the 1st quarter worth approximately $256,000. Institutional investors and hedge funds own 71.09% of the company’s stock.

Cardlytics Company Profile

Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.

Read More: How to Trade Using Analysts Ratings

Insider Buying and Selling by Quarter for Cardlytics (NASDAQ:CDLX)

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.